: iStockAnalyst.com Symbols Feed

ProActive HavRx Stock Indexes: Highlights And Opportunities

Sat, 07 Nov 2009 22:13:14 GMT

Below is a summary and some charts for popular and top performers among the 22 ProActive HavRx global stock indexes. Despite the FDA filing by Dendreon (NASDAQ: DNDN) during the past week, the underlying ImmunoTherapy / Vaccines Index is off to a slow start and down by about 10% since mid-October.[More...]

InvestmentNews: Health IT Investing, Index Mention

Thu, 05 Nov 2009 16:07:09 GMT

The Senior Editor of InvestmentNews, Jeff Benjamin, published an article today about investing in Healthcare Information Technology (Health IT) along with a reference to my Global Health IT Index and phone interview comments.[More...]

Momenta Pharma (MNTA): Timing Uncertain, Approval Likely for M-Enoxaparin

Tue, 06 Oct 2009 21:44:54 GMT

Momenta Pharma (NASDAQ: MNTA) presented at the 2009 UBS Global Life Sciences Conference about two weeks ago and outlined several key developments for the Company, including an update on the FDA status for M-Enoxaparin.[More...]

Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): A Good Buy

Fri, 02 Oct 2009 16:55:00 GMT

On September 30, Teva Pharmaceutical Industries Ltd (TEVA), sold the worldwide rights to a generic version of the white blood-cell boosting drug filgrastim to Hospira Inc (NYSE:HSP).[More...]

Mylan (NYSE: MYL): Patent Pending Profits

Wed, 16 Sep 2009 14:44:50 GMT

"It has been estimated that $100 billion of branded drugs will go off patent over the next five years and Mylan (NYSE: MYL) is very well positioned to benefit," says growth stock expert Tom Bishop.[More...]

Post Market Summary: Wall Street Ends Choppy Session Higher, General Electric (NYSE: GE) Gains

Mon, 14 Sep 2009 23:05:31 GMT

US stocks gained on Monday as investors shrugged off growing trade dispute with China.[More...]

US Stock Futures Points To Weaker Open, Sprint-Nextel (NYSE: S) In Focus

Mon, 14 Sep 2009 12:53:23 GMT

US stock futures retreated on Monday as investors were rattled by growing trade dispute between the U.S. and China. .[More...]

Merck (MRK) Wins Legal Battle

Thu, 20 Aug 2009 23:04:13 GMT

Merck (MRK) received a favorable ruling in a major patent-infringement suit yesterday against the largest generic player, Teva Pharmaceuticals (TEVA), on its top-selling drug Singulair. Teva was seeking the Food and Drug Administration’s (FDA) approval for selling a generic version of the drug for asthma and allergic rhinitis. The litigation has been continuing since Merck sued Teva in February 2007. During the second quarter of 2009, Singulair recorded worldwide sales of $1.3 billion, up 16% from the year-ago period. The drug had total sales of $4.3 billion in fiscal 2008, accounting for about 18% of Merck’s total revenue. Defending Singulair’s patent was thus quite crucial for Merck. We[More...]

Pharma Majors To Gain From India

Wed, 19 Aug 2009 03:28:58 GMT

All major pharmaceutical companies that have operations in India are likely to benefit from the latest decision made by the Commerce Ministry in that country. The ministry accepted the Mashelkar committee’s report, according to which India will continue to allow patents on incremental innovations if the enhancements are beneficial to patients. The decision was taken amidst severe protests from generic players and health activists who fear this will not allow cheaper generic drugs to enter the market. On the basis of 2008 sales figures, the Indian pharmaceutical market ranks 13th in the world, with sales of $7.7bn last year (an increase of 4% over 2007). The rapidly growing middle income group with higher disposable income makes it an attractive place for major pharma companies. The pharmaceutical market is expected to grow at 12.3% through 2014 surpassing many other economies in the emerging markets. Many of these[More...]

S&P 500 Stocks With Highest Short Interest

Mon, 13 Jul 2009 15:48:17 GMT

Going into earnings season it is always interesting to see which stocks have the highest short interest. The reason for that is if there are any "surprises" to the upside, these tend to be the stocks that take off like a rocket as shorts are forced to cover (buy). Courtesy of Bespoke blog we have an interesting list below - including many names we discuss, cover, or have shorted from time to time! (click to enlarge) [More...]

Mylan Reports Loss, Beats Estimates

Fri, 30 Oct 2009 16:48:00 GMT

Oct. 30--Generic drug maker Mylan Inc. sunk into the red in the third quarter after taking a charge to settle claims by the U.S. Justice Department that it inflated prices of drugs sold to Medicaid patients.
Excluding special items, Mylan said it earned 32 cents per share, beating analysts' consensus estimate of 27 cents.
Mylan CEO Robert Coury said that based on core results, the company was raising full-year earnings guidance to a range of $1.24 to $1.28 per share, excluding one-time items, up from $1.13 to $1.20.

: iStockAnalyst.com Symbols Feed

ProActive HavRx Stock Indexes: Highlights And Opportunities

InvestmentNews: Health IT Investing, Index Mention

Momenta Pharma (MNTA): Timing Uncertain, Approval Likely for M-Enoxaparin

Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): A Good Buy

Mylan (NYSE: MYL): Patent Pending Profits

Post Market Summary: Wall Street Ends Choppy Session Higher, General Electric (NYSE: GE) Gains

US Stock Futures Points To Weaker Open, Sprint-Nextel (NYSE: S) In Focus

Merck (MRK) Wins Legal Battle

Pharma Majors To Gain From India

S&P 500 Stocks With Highest Short Interest

Mylan Reports Loss, Beats Estimates

Mylan Earnings Down but Forecast Raised

Lang:WVU Still Violates Court Order: Judge Ruled Against Academic Hearing

Pittsburgh Post-Gazette Week in Review Column

Merck sued over patent on allergy drug Singulair

Pittsburgh Post-Gazette Heard Off the Street Column

USEC, Interpublic, Office Depot are big movers

Varian, Aetna, Plains Exploration are big movers

New York Hedge Fund Penalized for Not Disclosing Interests in Sale

Reversal of Fortune 500 Boosts Pittsburgh

PicksThatMove.com Announces Investment Opinion On: Mylan Laboratories Inc., Suncor Energy Inc., Romarco Minerals Inc., Nord Resources Corporation and Eastern Platinum Limited

Teva Comments on Mylan Paragraph IV Filing for COPAXONE®; Files Lawsuit Against Generic Filer for Patent Infringement

Audit Integrity Announces Results of Corporate Bankruptcy Study; Identifies Companies Most Likely to Declare Bankruptcy

Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment

Dey Issues Advisory

Mylan Files Lawsuit Against Pittsburgh Post-Gazette

Mylan's Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment

Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality

Mylan Receives FDA Approval for Generic Version of Migraine Treatment Imitrex(R)

President Clinton and Mylan Chairman and CEO Robert J. Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug-Resistant HIV in Developing Countries

Form 4 PARRISH MARK W For: Sep 01 (10K)

Form 3 PARRISH MARK W For: Sep 01 (10K)

Form 4 Varney Jolene L. For: Jun 08 (10K)

Form 3 Varney Jolene L. For: Jun 08 (10K)

Form 4 VANDERVEEN RANDALL L For: May 07 (10K)

Form 4 TODD C B For: May 07 (10K)

Form 4 PUSKAR MIKE For: May 07 (10K)

Form 4 Piatt Rodney L For: May 07 (10K)

Form 4 MAROON JOSEPH C MD For: May 07 (10K)

Form 4 LEECH DOUGLAS J For: May 07 (10K)